pbmi logo.png
Pharmacy Benefit Management Institute® (PBMI) announces open registration for PBMI MAP: Managing Access and Patient Care
February 23, 2024 12:00 ET | Pharmacy Benefit Management Institute®
CRANBURY, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- The Pharmacy Benefit Management Institute (PBMI), the nation’s leading provider of research and education on drug cost management, is pleased to...
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
February 22, 2024 08:27 ET | Moringa Acquisition Corp
                                       Silexion’s first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer...
American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis
February 22, 2024 08:00 ET | Bionano Genomics
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
February 22, 2024 08:00 ET | Cardiff Oncology, Inc.
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
February 22, 2024 06:19 ET | Curium
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Arvinas Announces Chief Financial Officer Transition
February 20, 2024 16:05 ET | Arvinas Inc.
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas,...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
February 20, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Immuneering-logo (1).png
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024 08:00 ET | Immuneering Corporation
– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase...
Nouveau Logo communiqué de presse.JPG
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
February 20, 2024 07:30 ET | Theratechnologies
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer...